News

Feb 18, 2013

Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia (Read more)

Feb 22, 2012

Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

Jul 24, 2011

Neurim Pharmaceuticals announces positive results from phase I and Ib clinical trials with Neu-P11, a sleep maintenance drug (Read more)

Jul 24, 2011

Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

Jun 22, 2011

Neurim Pharmaceuticals is currently performing a clinical trial in Korea to obtain Circadin® marketing authorization

Jun 16, 2011

Circadin® receives marketing authorization in New Zealand

May 17, 2011

Circadin® use approved for up to 3 months in Switzerland

Apr 4, 2011

Circadin® use approved for up to 3 months in Hong Kong

Jan 4, 2011

TGA approves Circadin® use for up to 3 months

Oct 4, 2010

Circadin® use approved for up to 3 months in Macedonia

Sep 6, 2010

Circadin® use approved for up to 3 months in Croatia

Jul 5, 2010

Circadin® approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months (Read more)

Apr 22, 2010

EMEA approves Circadin® use for up to 3 months

Jun 11, 2009

Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin® for Insomnia in Elderly Patients (Read more)

Sep 24, 2007

Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

Jul 6, 2007

Nycomed to market Circadin® for primary insomnia (Read more)

Jun 29, 2007

An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®

Apr 27, 2007

Neurim Pharmaceuticals announce that Circadin® for Primary Insomnia is recommended for approval in the EU (Read more)

Apr 26, 2007

Summary of positive opinion for Circadin® (EMEA Press Release) (Read more)